India, July 8 -- Annovis Bio, Inc.(ANVS), a clinical-stage biotechnology company, announced full enrollment of its pivotal Phase 3 trial evaluating Buntanetap in patients with early Alzheimer's disease or AD.
The trial enrolled 850 patients across 83 clinical sites in the US, diagnosed with early AD who are positive for the blood biomarker pTau217, which is a biomarker indicative of Alzheimer's pathology in the brain.
Annovis' lead drug candidate, Buntanetap, is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action.
Trial Details
The pivotal Phase 3 AD study is a rando...